Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 30 Nov 2015 |
| Genmab Announces Ofatumumab Phase III Study in Follicular Lymphoma to be Stopped Following Planned Interim Analysis | 23 Nov 2015 |
| Genmab Achieves USD 45 Million Milestone in DARZALEX™ (daratumumab) Collaboration with Janssen | 19 Nov 2015 |
| Major Shareholder Announcement | 17 Nov 2015 |
| Report Pursuant to Section 28a of the Danish Securities Trading Act | 17 Nov 2015 |